OF: Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women

Sponsor
Université de Sherbrooke (Other)
Overall Status
Completed
CT.gov ID
NCT01483612
Collaborator
Canadian Institutes of Health Research (CIHR) (Other), Ministere de la Sante et des Services Sociaux (Other)
130
1
2
81
1.6

Study Details

Study Description

Brief Summary

BACKGROUND: Obesity increases the risk of polycystic ovary syndrome (PCOS), characterized by anovulatory cycles, but it is also associated with reduced fertility even in ovulatory women. Moreover, obesity increases the costs of assisted human reproduction (AHR) treatments and reduces their efficacy. In addition to fertility disorders, obesity increases significantly the risks of many complications of pregnancy, delivery and neonatal health. However, a modest loss of 5-10% of total body weight can restore ovulation and improve pregnancy rates.

OBJECTIVES: 1) To design and implement a multidisciplinary program for lifestyle management of obese women, or overweight women with PCOS, who seek fertility treatment in a secondary AHR center. 2) To evaluate lifestyle benefits of this program and assess its impact on fertility, pregnancy and neonatal outcomes, as compared to a randomly assigned control group and to similar women seen in tertiary AHR centers. 3) To assess cost per live birth, and other measures of cost-effectiveness, of this program compared to the control group and tertiary AHR centers. 4) To effectively transfer knowledge obtained through these activities to relevant stakeholders in the health care and public health sectors.

METHODS AND APPROACH: In order to design the program for lifestyle management of obesity in infertile women, we will gather a Committee composed of members of our interdisciplinary research team and relevant collaborators. Objectives 2 and 3 - In order to achieve these objectives, 128 obese women (BMI ≥ 30 kg/m²), or overweight women with PCOS (BMI ≥ 27 kg/m²), consulting at the CHUS fertility clinic will be randomized to our lifestyle program, and will suspend fertility treatments for six months, or to standard fertility treatments, which are directly initiated. The results obtained will also be compared to those of women with the same criteria who will consult in 3 tertiary AHR clinics not offering a similar lifestyle management program.

IMPACT: This project is very important as it will generate new knowledge about the implementation, impacts and costs of a new lifestyle management program in obese infertile women. Our project will obtain valuable data on implementability of such a program; on benefits with regard to lifestyle, fertility and maternal and foetal complications during pregnancy; as well as on reduction in cost per live birth and other cost-effectiveness ratio.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Interdisciplinary lifestyle intervention
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
"Evaluation of Clinical Outcomes and Costs of a Transferable Interdisciplinary Lifestyle Intervention Pre- and Per-pregnancy in Obese Infertile Women"
Actual Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Aug 1, 2018
Actual Study Completion Date :
Aug 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lifestyle counseling

Behavioral: Interdisciplinary lifestyle intervention
Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting. The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity.
Other Names:
  • Lifestyle program for obese infertile women
  • No Intervention: control

    Outcome Measures

    Primary Outcome Measures

    1. Rates of live birth [Participants who will become pregnant: for the duration before they get pregnant and up to the end of pregnancy, an expected average of 18 months. Participants who will not become pregnant: 18 months]

    Secondary Outcome Measures

    1. Fertility outcomes [18 months]

    2. Pregnancy outcomes [Participants who will become pregnant: up to the end of pregnancy, an expected average of 18 months of follow-up in the study]

    3. Neonatal outcomes [Participants who will become pregnant: up to the end of pregnancy, an expected average of 18 months of follow-up in the study]

    4. Clinical outcomes [18 months]

      Evolution of anthropometric measures, change in lifestyle habits, physical fitness level and evolution of readiness for change.

    5. Cost per life birth, and other measures of cost-effectiveness [Participants who will become pregnant: for the duration before they get pregnant and up to the end of pregnancy, an expected average of 18 months. Participants who will not become pregnant: 18 months]

      All costs (interventions and complications) to achieve one life birth, including either all women with a life birth or all enrolled women (by intervention arm).

    6. Clinical outcomes in male partners [18 months]

      Evolution of anthropometric measures and change in lifestyle habits in male partners.

    7. Clinical outcomes of female participants [18 months]

      Evolution of anthropometric measures, changes in lifestyle habits (diet, exercise, alcohol, tobacco), physical fitness level, evolution of readiness for change, etc.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Obese (BMI ≥ 30kg/m2) infertile women

    • Overweight (BMI ≥ 27kg/m2) infertile women with polycystic ovary syndrome

    Exclusion Criteria:
    • Women older than 40 years old

    • Women who went through bariatric surgery

    • Women under IVF

    • Women for whome IVF is the only recommended treatment

    • Women who do not speak french

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre hospitalier universitaire de Sherbrooke Sherbrooke Quebec Canada J1H 5N4

    Sponsors and Collaborators

    • Université de Sherbrooke
    • Canadian Institutes of Health Research (CIHR)
    • Ministere de la Sante et des Services Sociaux

    Investigators

    • Principal Investigator: Jean-Patrice Baillargeon, MD, Université de Sherbrooke

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jean-Patrice Baillargeon, Associate Professor, Université de Sherbrooke
    ClinicalTrials.gov Identifier:
    NCT01483612
    Other Study ID Numbers:
    • CIHR/FRN-114125
    First Posted:
    Dec 1, 2011
    Last Update Posted:
    Apr 30, 2021
    Last Verified:
    Apr 1, 2021

    Study Results

    No Results Posted as of Apr 30, 2021